InVeris Training Solutions Unveils SRCE™ – a Revolutionary, Augmented Reality Training System

 SUWANEE, Ga-Tuesday 30 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- InVeris Training Solutions, the leading provider of integrated live-fire and virtual weapons training systems for military, law enforcement agencies and commercial shooting ranges, today unveils SRCE™ (See, Rehearse, Collectively Experience or "Source"), a groundbreaking, augmented reality-based, untethered weapons training simulator. InVeris Training Solutions provides the most advanced augmented reality technology available in a military and law enforcement training simulator, a feat previously thought to be years away by many in the industry.

"Augmented reality delivers the best of the virtual and real worlds in a way that's fully lifelike, seamless, customizable and economical," said InVeris CEO Al Weggeman. "Physical training facilities can be scanned and augmented to become instant shoot houses by integrating outside content in just minutes. More importantly, we can compare and measure individual and team performance with high precision real-time location tracking of every participant, weapon and even ammunition round."

Critical, use-of-force training can now occur at the point of need or anywhere in the world. This never-experienced complete immersive technology delivers a way to see, rehearse and collectively experience techniques, tactics and procedures with real-time location, movement, orientation and biometric sensing for training and operations. SRCE's proprietary scanning technology allows an instructor to capture the space intended for use as a shoot house using a tablet or other device with a high-resolution camera. Hostile forces, suspects, decoys, hostages, and other parties are all delivered digitally, eliminating the need for opposition role players. SRCE's ability to create a virtual shoot house on the fly lends to active shooter and mission rehearsal training. Wearable, untethered technology, including an AR head-mounted display, provides realistic immersion without compromising freedom of movement and is fully compatible with InVeris' highly accurate BlueFire® simulated weapons.

The unparalleled interactive after-action review (AAR) collects performance data for statistical analysis of never-before-available parameters, including muzzle direction, weapon discharge, missed rounds, eye tracking and head placement. Body sensors monitor a trainee's heart rate, breathing, gaze and other biological signs in real-time. Trainees can even walk through their previous session, seeing every element played back around them as a visualization to review operational performance. This highly immersive AAR creates the optimal opportunity for instructors to increase training fidelity and retention.

For more information on SRCE, visit https://www.inveristraining.com/srce.

About InVeris Training Solutions

InVeris Training Solutions provides cutting-edge training solutions for militaries, law enforcement agencies and commercial range owners around the world. With its legacy companies, FATS^® and Caswell, InVeris Training Solutions has fielded over 15,500 live-fire ranges and 7,500 virtual systems globally during its 95-year history. The company is headquartered in Suwanee, Georgia and partners with clients in the U.S. and around the world from facilities on five continents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005628/en/

---

Contacts

Michelle Henderson
Director of Marketing
InVeris Training Solutions
+1-678-288-1090
michelle.henderson@inveristraining.com

 

Permalink : https://www.aetoswire.com/news/inveris-training-solutions-unveils-srcetrade-ndash-a-revolutionary-augmented-reality-training-system/en

 

Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India

 NEUCHATEL, Switzerland-Monday 29 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced the findings of a study published in Clinical Medicine Insights: Pediatrics in which Dr. Harish Kumar and colleagues at IPE Global in New Delhi, India reported on their experience using the Masimo Rad-G® Pulse Oximeter to aid health providers in pneumonia case detection and management in more than 4,500 children under five years who presented with symptoms of acute respiratory infection (ARI). Rad-G is a rugged, portable, handheld Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximeter and noninvasive respiration rate monitor from the pleth (RRp®). The researchers found that Rad-G was “highly acceptable among health workers” and aided the “timely classification and treatment” of pneumonia—helping them achieve correct case management in more than 91% of cases of ARI and reduce the unnecessary use of antibiotics.1

Study author Dr. Kumar commented, “Our decision to choose Rad-G as our pulse oximeter of choice to aid HWCs in pneumonia screening proved to be a good one. The device is easy to use and maintain, even in low-resource settings, and because of its ability to accurately and reliably measure SpO2 and RR, it has the potential to transform the identification and management of pneumonia by healthcare workers, even those who may not be medical doctors. We hope that our study will help convince many more Indian states of the value of integrating use of Rad-G and its technological benefits into their care practices, supporting nationwide efforts to successfully diagnose and treat as many cases of pediatric pneumonia as possible.”

As the authors note, pneumonia – one of the most common causes of ARI in children – contributes to 15% of child deaths across the world, with India accounting for 20% of those deaths. In low-resource health settings, where access to diagnostic aids is limited, health workers often rely on manual counts of respiratory rate to inform ARI management decisions. In this trial, researchers evaluated oxygen saturation (SpO2) and respiratory rate (in accordance with WHO guidelines for effective pneumonia management) measured by Rad-G. Given the often “inadequate skills” of front-line healthcare workers in low-resource and rural settings—for example, it was found that the majority of workers at Indian Health and Wellness Centers (HWCs) “lacked knowledge on how to correctly assess a child with cough or difficult breathing”—the authors hoped that Rad-G could help workers more readily diagnose pneumonia, prove to offer good “usability,” and ultimately, contribute to India’s goal of aggressively reducing child deaths due to pneumonia.

The researchers chose Rad-G from among other available pulse oximeters for a variety of reasons, in particular its integration of respiration rate from the pleth (RRp) and accurate and reliable SpO2. Before proceeding with this larger trial, an initial study at a single tertiary care hospital was conducted in 2019 to evaluate the accuracy of RRp on Rad-G. That study found a 97% association between Rad-G RRp and pediatrician-measured RR, with high sensitivity, specificity, and accuracy.2 The authors also noted Rad-G’s long-lasting, rechargeable battery, its LCD display, and the fact that a single sensor could be used on all children under five years. Following the initial study, Rad-G was introduced at 19 HWCs across seven states in India, and its implementation and utility (including usability and durability) were tracked over 15 months, from June 2019 to August 2020. Over this period, a total of 4,846 children aged 2 – 60 months with symptoms of ARI visited the facilities. To aid in assessing cases, providers were given abridged training in India’s Integrated Management of Neonatal and Childhood Illnesses (IMNCI) program, which classifies children with ARI as having severe pneumonia (SpO2 < 90% or presence of “general danger signs”), pneumonia (fast breathing or chest in-drawing), or neither (none of the above).

Of the 4,846 children, 0.1% were diagnosed with severe pneumonia and 23% with pneumonia. Reviewing cases on a monthly basis, the researchers found that 91.4% of all cases were correctly managed. In addition, 12 children with severe pneumonia, who were referred, would have been missed without the use of Rad-G pulse oximetry.

The researchers concluded, “The pulse oximeter implementation was found to integrate well within a primary healthcare level. The robustness and ease of usability of the device is perhaps the biggest advantage observed, which has led to some of the states budgeting for PO [pulse oximetry] for scale-up in all the districts. A rigorous evaluation in scaled up facilities should be considered by the government. The implementation tentatively demonstrates that a systematic approach to diagnosing pneumonia is likely to improve case management.”

The authors also noted, “Considering the importance of hypoxemia and fast breathing as a sign of severe illness, an ideal pulse oximeter is one which functions as a point-of-care device, is durable, affordable, easy to maintain and can deliver rapid, reliable noninvasive SpO2 measurements. A device that measures respiratory rate should also be considered for wider usage given the difficulty among healthcare workers [of] measur[ing] respiratory rate manually. Improving case management of pneumonia at the primary care level by expanding ARI diagnostic aids, while also increasing coverage of IMNCI, strengthening referral pathways, and improving quality of care in referral facilities, will contribute majorly to the SDG [Sustainable Development Goal] goal of reducing under-5 mortality.”

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,10 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2021-22 U.S. News and World Report Best Hospitals Honor Roll.11 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView®, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

Kumar H, Sarin E, Saboth P, Jaiswal A, Chaudhary N, Mohanty J, Bisht N, Tomar S, Gupta A, Panda R, Patel R, Kumar A, Gupta S, Alwadhi V. Experiences from an Implementation Model of ARI Diagnostic Device in Pneumonia Case Management Among Under-5 Children in Peripheral Healthcare Centers in India. Clin Med Insights: Pediatrics. 2021;(15)1-10. DOI: 10.1177/11795565211056649.
Alwadhi V, Sarin E, Kumar P, Saboth P, Khera A, Gupta S, Kumar H. Measuring accuracy of plethysmography based respiratory rate measurement using pulse oximeter at a tertiary hospital in India. Pneumonia. 2020. 12:4.. https://doi.org/10.1186/s41479-020-00067-2
Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
Estimate: Masimo data on file.
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Rad-G®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Rad-G, contribute to positive clinical outcomes and patient safety; risks that the researchers’ conclusions and findings may be inaccurate; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211128005235/en/

Contacts
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com





Permalink : https://www.aetoswire.com/news/masimo-rad-gregnbsphelps-clinicians-identify-pediatric-pneumonia-in-large-field-trial-in-india/en

Vifor Pharma announces changes to the Executive Committee as CFO retires

 • Colin Bond to retire as Chief Financial Officer of Vifor Pharma Group

• Succession recruitment ongoing

ST. GALLEN, Switzerland-Tuesday 30 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021 at his own request. Vifor Pharma is currently in the recruiting process for the new Chief Financial Officer, to be announced once the successor has been identified.

Abbas Hussain, Chief Executive Officer of Vifor Pharma, commented: "On behalf of the company I would like to thank Colin for his valuable contributions and leadership during his tenure at Vifor Pharma. For his next phase of his life I wish him all the best and satisfaction in his future endeavors.”

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005611/en/

---

Contacts

Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

 

Permalink : https://www.aetoswire.com/news/vifor-pharma-announces-changes-to-the-executive-committee-as-cfo-retires/en

 

 

​​​​​​​​​​​​​​Galderma to Acquire Award-winning ALASTIN Skincare® Enhancing Its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients

  ALASTIN Skincare® was the fastest growing brand in the U.S. professional skincare market in 20201

 ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio

 Galderma will support further product innovation and geographical expansion of ALASTIN’s portfolio





ZUG, Switzerland & CARLSBAD, Calif-Monday 29 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The acquisition is subject to customary closing conditions and necessary regulatory approvals. Financial terms of the transaction have not been disclosed.

ALASTIN’s premium skincare portfolio is fully incremental to and synergistic with Galderma’s integrated dermatology platform. Founded in 2015, ALASTIN provides a comprehensive collection of cutting-edge, scientifically-proven products for daily skincare regimens and peri-procedural use. ALASTIN’s product offerings are backed by its patented TriHex Technology®, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. Since inception, ALASTIN has delivered rapid and consistent sales growth, achieving a CAGR of 106% between 2016 and 2020, one of the highest of any professional skincare company. ALASTIN Skincare® was ranked the No. 1 preferred skincare brand in a blinded survey of physicians who carry ALASTIN and other skincare brands, conducted by Corsica Life Sciences in December 2020. The company was named as one of Forbes best start-up employers in America in 2020 and 2021 and was named as one of the fastest growing private companies in America on the INC 5000 2020 and 2021 lists.

"Galderma’s business consistently delivers strong results and remains at the forefront of this rapidly expanding market, driven by increasing consumer interest and acceptance of aesthetic procedures. The addition of ALASTIN, with its synergistic portfolio and expertise in science-proven skincare, increases our ability to serve the needs of consumers and underscores our commitment to be the partner of choice for aesthetic professionals.

“This transaction will further enhance our premium product offering and provides a tremendous platform for future growth. We look forward to welcoming the ALASTIN team into Galderma and partnering with them to advance the science of dermatology together."

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

By leveraging its global reach and integrated dermatology platform, Galderma will unlock ALASTIN’s next growth phase as it reaches more healthcare professionals and consumers more effectively. Galderma will also support further product innovation of ALASTIN’s portfolio, while simultaneously enabling cross-selling opportunities for ALASTIN’s products and technologies in the U.S. Combining Galderma’s world class pipeline and track record of first-to-market innovation with ALASTIN’s proprietary and award-winning skincare technology represents an unparalleled opportunity for Galderma to better meet the needs of aesthetic professionals and patients.

"We are thrilled to become part of Galderma for the next stage of ALASTIN’s growth story. We share the same vision of bringing the highest levels of science and innovation to the professional skincare market, and I look forward to working with the team to leverage Galderma’s expertise in this space to drive the ALASTIN Skincare® brand to new heights.”

DIANE S. GOOSTREE
PRESIDENT AND CEO
ALASTIN SKINCARE

Ropes & Gray LLP is acting as legal advisor to Galderma, and Latham & Watkins LLP is acting as legal advisor to ALASTIN. William Blair & Company, LLC is serving as the exclusive financial advisor to ALASTIN.

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.

About ALASTIN
ALASTIN Skincare® is the fastest-growing physician-dispensed skincare brand, with innovative, scientifically-proven and clinically-tested products. Founded in 2015, ALASTIN Skincare, Inc. provides a comprehensive collection of cutting-edge products for daily skincare regimens and peri-procedural use. We strategically focus research and development on innovative products with the greatest potential impact for patients and providers. Our team’s mission is to bring the highest levels of pharmaceutical science and innovation to the physician-dispensed skincare industry while creating a new category of products designed to be synergistic with procedures.

1 Kline Group’s 2020 Professional Skincare: U.S. Market Analysis and Opportunities report

View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005282/en/

Contacts
Media Contact

Galderma
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Shannon Iwaniuk
Global Communications, US
shannon.iwaniuk@galderma.com
+1 720 308 1336

ALASTIN
Media Contact
Holly Curtis
holly@blendedstrategy.com




Permalink : https://www.aetoswire.com/news/galderma-to-acquire-award-winning-alastin-skincareregnbspenhancing-its-integrated-dermatology-platform-to-continue-delivering-the-best-experience-to-patients/en

Aster Guardians Global Nursing Award worth US $250,000 now open for nominations from nurses worldwide

Dubai, United Arab Emirates-Monday 29 November 2021 [ AETOS Wire ]

The winner of the First Prize would be awarded US $ 250,000 while 9 other finalists would be receiving substantial monetary prize at a grand ceremony in Dubai on International Nurses Day on 12th May, 2022.

Nurses from around the world can submit their nominations via www.asterguardians.com by 30th January, 2022.

 

Launched on International Nurses Day in May 2021 by Aster DM Healthcare, with an aim to recognize the phenomenal contribution of nurses to the healthcare delivery system globally, Aster Guardians Global Nursing Award has started receiving applications from nurses worldwide. The application system is completely online via www.asterguardians.com, where a nurse can submit her own application for the award or anyone can nominate a nurse, who they think is worthy of the award.

Aster has appointed Ernst & Young LLP (EY) as ‘Process Advisors’ who would ensure due-diligence of applications based on the defined eligibility criteria, evaluation of the entries by an independent panel of experts, and presentation by the finalists to an independent well-known Jury to determine the final winner.

Encouraging nurses from around the world to apply and nominate nurses for the award, Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “Nurses are the unsung heroes of the healthcare system which has been proven undoubtedly during the Covid-19 pandemic. They continue to play a pivotal role and are the backbone of the healthcare delivery system working under tremendous pressure with huge commitment. Aster Guardians Global Nursing Award is our effort to recognize the phenomenal work being done by the nursing community worldwide. With over 7000 nurses in the Group, we consider it our obligation to recognize and celebrate the contribution of nurses across the world.”

Aster Guardians Global Nursing Award has started receiving nominations from nurses based in Middle East, Indian sub-continent, Africa, North and South America, Central Asia, Europe and Oceania. The last date for accepting nominations is 30th January, 2022, post which the review process will start. After the initial review based on the set criteria, shortlisted nominations will undergo a voting process. Subsequently 10 finalists would be selected for the award ceremony, interview, and interactions with the jury. The final Aster Guardian Global Nursing Award winner will be announced on 12th May- International Nurses Day in 2022 at a grand ceremony in Dubai. Apart from the substantial First Prize of US $ 250,000, the 9 finalists will also be presented with monetary prize and awards.

 

About Aster DM Healthcare

Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare through our 27 hospitals, 117 clinics and 225 pharmacies in seven countries, including India. We have over 23,100 plus dedicated staff including 3,029 doctors and 6,729 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: “We’ll treat you well.” We reach out to all economic segments in the GCC states through our differentiated healthcare services across the “Aster”, “Medcare” and “Access” brands.

 

DISCLAIMER:

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Aster DM Healthcare will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Contacts

Lavanya Mandal                                                                                                   

Head of PR and Internal Communications                                          

Aster DM Healthcare

Tel:  +971 528126577

Email: lavanya.mandal@asterdmhealthcare.com

 

Bejoy Changarath

Assistant General Manager - PR & Media Relations

Aster DM Healthcare

Tel: +971 524073559

Email: bejoy.changarath@asterdmhealthcare.com

 

Permalink : https://www.aetoswire.com/news/aster-guardians-global-nursing-award-worth-us-250000-now-open-for-nominations-from-nurses-worldwide/en

EXPANSION OF JUBAIL COMMERCIAL PORT PAVES THE WAY FOR A GREENER, SAFER, AND MORE COST-EFFICIENT TRANSPORT OPTION.

  $50 million upgrade enables the entire Eastern Province export market to ship through Jubail port



Jubail, Saudi Arabia -Tuesday 23 November 2021 [ AETOS Wire ]

Gulf Stevedoring Contracting Company (GSCCO), part of the Gulftainer group of companies, has announced enhancements to Jubail Commercial Port. With the completed upgrades, the port now has the capacity to process 1.8 million twenty-foot containers (TEU's) per year.

By increasing export volumes in Jubail, The Kingdom of Saudi Arabia exporters will have the ability to directly reduce carbon emissions. According to the World Economic Forum, moving cargo by truck accounts for approximately 25 percent of global transport emissions. Although 60 percent of containers processed by cargo operators in the Jubail region are currently moved via the port, the remaining 40 percent is transported via the Dammam highway. Exporters with ambitious carbon neutrality goals can take an average of 101 km off the road with each container moved over Jubail.

Congestion and traffic accidents on the highway frequently delay access to the Eastern Province and congest the surrounding hinterland. By upgrading Jubail's throughput capabilities, cargo owners will be able to directly improve road safety and ensure the integrity of KSA's critical oil and gas supply chain.

Jason French, Managing Director of GSCCO, said: "As we upgrade the Jubail Commercial Port, we continue to work with the Saudi Ports Authority, Mawani, and other key stakeholders, including SABIC and Sadara, to divert the transportation of containers to the port. GSCCO is committed to the principles outlined in the Saudi Vision 2030 and the Saudi Green Initiative, under the patronage of HRH Crown Prince Mohammed bin Salman, to offset the impact of fossil fuels and reduce adverse effects on the climate. According to our in-house experts, moving containers by truck to Dammam instead of using the local Port of Jubail accounts for the emission of 26.1 million kilograms of carbon per annum. It clearly makes economic and environmental sense to transport goods via Jubail Port."

Strategically located, this multipurpose port can handle container, bulk, and general cargo and is critical to the economic development in the Kingdom of Saudi Arabia.

About GSCCO

Founded in 1985, the Gulf Stevedoring Contracting Company (GSCCO) is one of the most notable port operators in Saudi Arabia. Based in the heart of the Berry Oil Field in Jubail, the company has a history of over 35 years of managing 14 port concessions.

GSCCO is an expert in providing efficient supply chain solutions, making it a leading figure in the KSA maritime port sector. It is the only terminal operator in the country that has handled over 35 million TEUs and 10 million tonnes of general cargo.

In 2013, GSCCO became part of Gulftainer group, one of the leading privately owned and independent terminal operators in the world, which is based in Sharjah, UAE. For more information on GSCCO, visit https://www.gulfstevedoring.com/website/

About Gulftainer

Established in 1976, Gulftainer is a privately owned, independent port management and 3PL logistics company based in the United Arab Emirates (UAE) and for more than 45 years it has been delivering a world-class performance to its customers. Its global footprint including operations in the UAE, Iraq, Saudi Arabia, and the USA.

Gulftainer is excited to create an open, collaborative platform to lead the port industry’s revolution, engaging startups, entrepreneurs, and other stakeholders to create the future of the ports and logistics industry. For more information on Gulftainer, visit www.gulftainer.com

For further information please contact:

Gulftainer

Global:

Neena Dominic, Gulftainer Communications

(M) +971 50 2861274  (E) communications@gulftainer.com

US:        

Kathryn Bradley, Gulftainer Communications

(M) +1 302 354 4096 (E) communications@gulftainer.com

Contacts

Raneem Al Banna

Tel: +97143298996

r.albanna@saharapr.com

Permalink : https://www.aetoswire.com/news/expansion-of-jubail-commercial-port-paves-the-way-for-a-greener-safer-and-more-cost-efficient-transport-optionnbsp/en

Merck Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus

 DARMSTADT, Germany -Monday 22 November 2021 [ AETOS Wire ]

5 potential first-in-class assets aimed at delivering significant long-term growth

14 clinical development programs underway across portfolio

11 new studies to start in 2022 across early- and late-stage pipeline

(BUSINESS WIRE)-- Merck, a leading science and technology company, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call.

“At Merck we are working to translate our extensive expertise and deep knowledge in key tumors and neurological and immunological diseases with a goal to change treatment paradigms and improve patient outcomes,” said Danny Bar-Zohar, Global Head of Development for the Healthcare business of Merck. “With evobrutinib, xevinapant, and berzosertib, we have the opportunity to be not only first-in-class, but potential game-changers in how we treat MS, head & neck cancer and small cell lung cancer going forward.”

Advancing Assets with Transformational Potential

Evobrutinib (BTK inhibitor) – A pioneering development program with a new mechanism of action (MoA) for the treatment of patients with relapsing multiple sclerosis (RMS) that has the potential to change the standard of care.

Oral, central nervous system (CNS)-penetrant, covalent Bruton’s tyrosine kinase inhibitor (BTKi) in development for RMS.

MoA combines potent B-cell inhibition to target acute inflammation (associated with relapses) with a central effect on microglia that aims to reduce chronic inflammation (associated with disease progression).

Comprehensive Phase II clinical data support best-in-class potential.

Evobrutinib is the first BTKi to have completed enrollment of the Phase III clinical trial program for relapsing multiple sclerosis, with data readout expected in Q4 2023.

Xevinapant (IAP antagonist) – As a potent oral antagonist of Inhibitor of Apoptosis Proteins (IAP) and the only IAP antagonist in late-stage development, xevinapant builds on our market-leading expertise in squamous cell carcinoma of the head and neck (SCCHN), aimed at maximizing the chances of a cure in locally advanced disease setting.

Ongoing Phase III TrilynX study for previously untreated unresectable locally advanced (LA) SCCHN in combination with platinum-based chemoradiotherapy.

Second global Phase III study to be initiated in the first half of 2022 to evaluate xevinapant in patients with cisplatin-ineligible LA SCCHN.

5-year update of OS data from Phase II study anticipated in 2022.

First launch expected in 2025.

Berzosertib (ATR inhibitor) – The lead candidate in our DNA Damage Response (DDR) inhibitor portfolio and the first ATR inhibitor with positive randomized clinical trial in any tumor type, seeks to exploit the synergistic effect of combining ATR inhibition with topoisomerase I inhibitors

Multiple mid-stage clinical trials in small cell lung cancer (SCLC) build on positive Phase II study results, with the goal of establishing a new standard of care in second-line SCLC.

Study planned for indication expansion in ovarian cancer and potentially in refractory GI cancers.

M1231 (MUC1/EGFR bi-specific ADC) – The first bi-specific ADC (antibody-drug conjugate) from our pipeline that aims to optimize targeting of cancer cells and overcome remaining safety limitations of conventional ADCs.

M1231 delivers a cytotoxic payload to tumor cells expressing both MUC1 and EGFR and has a highly controlled drug-antibody ratio, which is anticipated to increase tumor specificity, selectivity, and efficacy.

Phase I clinical study to characterize the safety and preliminary activity is well underway, and efficacy expansions into late-stage non-small cell lung cancer and esophageal squamous cell carcinoma are expected to begin in 2022.

Enpatoran (TLR7/8 inhibitor) – Oral therapy that aims to overcome limitations of available lupus therapies by providing selective inhibition of lupus-relevant disease drivers, which may increase efficacy while preserving immunity against infections.

Highly specific potential first-in-class immune modulator blocking the activation of Toll-like receptor (TLR)7 and TLR8, known to be activated in lupus.

Initiation of Phase II studies in systemic lupus erythematosus (SLE) / cutaneous lupus erythematosus (CLE) in the first half of 2022.

Advancing the broader pipeline and portfolio

Merck will initiate 11 new studies in 2022 across the early- and late-stage pipeline, including a Phase III confirmatory study with tepotinib in EGFRm MET amplification in NSCLC, five proof-of-concept studies including trials of M1774, an oral ATR inhibitor being evaluated as both a monotherapy and in combination with PARP inhibitors; the JAVELIN Bladder Medley umbrella study in the first-line urothelial carcinoma, combining avelumab with novel investigational agents including our anti-TIGIT M6223 and Nektar Therapeutics’ interleukin-15 (IL-15) receptor agonist, NKTR-255, in the maintenance setting; two first-in-human studies involving M9140, a next-generation ADC based on an internally developed linker-payload technology; and M1069, our dual adenosine receptor antagonist.

“Our rapidly progressing pipeline of in-house–discovered and partnered assets with first-in-class potential demonstrate the deep expertise and collaborative mindset of our R&D organization,” said Joern-Peter Halle, Global Head of Research for the Healthcare business of Merck. “We expect exciting new entries and substantial advances of our early- and late-stage pipeline in the next few years.”

To access the presentation and a recording, please visit the Company’s website at https://www.merckgroup.com/en/investors/events-and-presentations.html.

Merck’s Commitment to Cancer

Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at https://www.merckgrouponcology.com.

Merck in Neurology and Immunology

Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).

Follow us on Twitter @MerckHealthcare and LinkedIn @Healthcare Business of Merck.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005062/en/

Contacts

Media Relations

gangolf.schrimpf@merckgroup.com

Phone: +49 151 1454 9591

Investor Relations

investor.relations@merckgroup.com

Phone: +49 6151 72-3321

Permalink : https://www.aetoswire.com/news/merck-highlights-novel-mechanisms-with-the-potential-to-transform-standards-of-care-in-several-cancers-ms-and-lupus/en

LightCON Unveils Global Teaser Site for New Mobile Game 'Rise of Stars (ROS)'

 SEONGNAM, South Korea -Friday 26 November 2021 [ AETOS Wire ]

Opened the global teaser site for the new title ‘Rise of Stars (ROS)’
SF strategy game developed on WEMIX
Aiming for a global launch in the 1st quarter of 2022
(BUSINESS WIRE)-- Rise of Stars (ROS), a new mobile game that is being developed by LightCON, a subsidiary of WEMADE MAX (Co-CEOs: Hyunguk Chang, Gilhyung Lee) (KOSDAQ: 101730), today opened its global teaser site.

Under the slogan, ‘The 4x Blockchain Game for the Greatest Conqueror,’ the teaser site was designed to help users experience the unique atmosphere of ROS and the game concept with the representative image of the game.

ROS is a new mobile SF strategy game featuring elaborately designed warships and planets set in the vast universe.

It has also fun elements, such as for players to find planets with rich resources in the galaxy and engage in battles against opponents, in addition to the strategic planning to expand power through real-time massive warfare.

At the same time, ROS will be building a system for players to obtain game tokens through resource mining within planets.

Through the application of Wemade’s blockchain technology, ROS will introduce a new game token and also a non-fungible token (NFT) on WEMIX platform.

ROS will be globally serviced under the title, ‘Rise of Stars on WEMIX.’ Making every effort to ensure a successful global service launch in the first quarter of next year, ROS will release the game information and play videos sequentially following the opening of the teaser site.

* 'Rise of Stars' Teaser site: https://www.riseofstars.io

View source version on businesswire.com: https://www.businesswire.com/news/home/20211125006252/en/

Contacts
For LightCON
Wemade Co., Ltd.
Young Ahn
+82-2-3709-2065
ay2000@wemade.com





Permalink : https://www.aetoswire.com/news/lightcon-unveils-global-teaser-site-for-new-mobile-game-39rise-of-stars-ros39/en

Women’s Entrepreneurship Accelerator Partners with the WE Empower UN SDG Challenge to Maximize the Development Impact of Women Entrepreneurs

 Entrepreneurs The WE Empower Challenge, a Programme co-led by Vital Voices & the Global Futures Laboratory at Arizona State University, is a First-of-its-Kind Competition for Women Social Entrepreneurs


NEW YORK-Monday 22 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- The Women’s Entrepreneurship Accelerator (WEA), a strategic multi-partnership convening five United Nations agencies and Mary Kay, Inc., in support of last week Global Entrepreneurship Week and Women’s Entrepreneurship Day, announced a partnership with WE Empower UN SDG challenge, a first-of-its-kind competition for women social entrepreneurs across the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211120005125/en/

WEA is designed to maximize the development impact of women entrepreneurship in achieving the UN Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs that fosters growth, sustainability, and resilience. UN Partners of WEA include International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), and UN Women.

The WE Empower UN SDG Challenge is a global business competition for women entrepreneurs who are advancing the UN Sustainable Development Goals and inspiring entire communities to act to create the world they want by 2030. The WE Empower UN SDG Challenge honors women entrepreneurs who are advancing the SDGs through their business practices. The opportunity recognizes their innovative work, ignites awareness about the valuable contribution women entrepreneurs can make toward the SDGs, and provides awardees with capacity-building training sessions and connections with business experts around the world.

The programme elevates and showcases the valuable contributions women entrepreneurs and business leaders can make toward the SDGs and solving the world’s greatest challenges. WE Empower is co-led by Vital Voices and Julie Ann Wrigley Global Futures Laboratory at ASU and supported by partners at Bank of Montréal (BMO), Diane von Furstenberg, the G5 Collective, GroYourBiz, Hawaii Tropical Botanical Garden, Mary Kay, Inc., Oxford University Said Business School, Procter & Gamble, Salesforce, UN Foundation, and the World Bank.

“The WE Empower SDG Challenge powerfully showcases women entrepreneurs as ideal role models demonstrating positive business, social and environmental performance,” said Deborah Gibbins, Chief Operating Officer at Mary Kay, Inc. “The Women’s Entrepreneurship Accelerator is honored to partner with WE Empower, a consortium of over 70 partners joining forces for an even greater multiplied impact.”

“We are thrilled to celebrate our partnership with the Women’s Entrepreneurship Accelerator, co-founded by WE Empower lead partner Mary Kay, Inc.,” said WE Empower UN SDG Challenge co-chair & ASU Julie Ann Wrigley Global Futures Laboratory’s Amanda Ellis. “Women entrepreneurs are valuable solutionaries for the UN SDGs and the global 2030 agenda, and WEA unlocks a suite of valuable support tools to help amplify positive impact.”

Globally, women already comprise one-third of all business owners, making critical economic and social contributions, despite the systemic barriers they face. Only five percent of countries legislate for full gender equality, making the support tools provided by the Women’s Entrepreneurship Accelerator even more important. In June 2021, WEA joined the Generation Equality Forum in Paris as well as the Action Coalition on Economic Justice and Rights, and committed to empower five million women entrepreneurs around the world by 2030 to accelerate progress for gender equality.

During UN General Assembly (UNGA 76), WEA announced the launch of a series of impactful initiatives and knowledge products - all shaped through a gender lens. WEA’s impact work includes digital capacity building tools and training, entrepreneurship and policy research, and gender-responsive procurement (GRP) advocacy and training. In October, WEA also announced a milestone partnership with the Commonwealth Businesswomen’s Network (CBWN) aiming at advancing women entrepreneurship in 54 countries of the Commonwealth.

About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-partnership initiative on women’s entrepreneurship convening 5 UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), UN Women and Mary Kay, Inc. to empower 5 million women entrepreneurs by 2030.

The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.

Learn more at we-accelerate. Follow us: Twitter (@We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)

About WE Empower UN SDG Challenge
The WE Empower UN SDG Challenge is the first-of-its-kind global competition for women social entrepreneurs who are advancing the UN Sustainable Development Goals and inspiring entire communities to act to create the world we want by 2030. The WE Empower Challenge honors innovative women leaders from around the world who are pushing the SDGs forward through sustainable business practices and inspiring others to follow suit. The opportunity recognizes their innovative work and provides Awardees with capacity-building training sessions and opportunities to connect with an unparalleled global network to advance their enterprises. This program elevates and showcases the valuable contribution women entrepreneurs and business leaders can make toward the SDGs and solving the world’s greatest challenges.

About Vital Voices Global Partnership
Vital Voices Global Partnership is an international non-profit organization that identifies and partners with creative and fearless women leaders around the world. Vital Voices searches the world for women leaders with daring vision for change, then works with them to make that vision a reality. We are venture catalysts, who provide leaders with capacity building, skills training, grants, access to a network of their peers, mentorship, visibility, recognition, and guidance to accelerate change on a global scale. For more than 20 years, Vital Voices has invested in over 18,000 women leaders from 182 countries and territories, who have then gone on to create change affecting millions around the world. Vital Voices works with women who advance economic opportunity, increase political and public engagement, end gender-based violence and promote human rights through signature fellowships, individualized investments and meaningful, lifelong partnerships. Vital Voices connects women solving problems in their communities and equips them with the tools they need to incite global, positive change and accelerate shared progress for all. Visit www.vitalvoices.org to learn more.

About Julie Ann Wrigley Global Futures Laboratory at ASU
The Julie Ann Wrigley Global Futures Laboratory at Arizona State University represents the urgent belief that we can and must make a meaningful contribution to ensuring a habitable planet and a future in which well-being is attainable. The Global Futures Laboratory is the world’s first laboratory dedicated to the health of the planet and its inhabitants. It is built upon the deep expertise of ASU and leveraging an extensive network of partners for an ongoing and wide-ranging exchange across all knowledge domains to address the complex social, economic and scientific challenges spawned by the current and future threats from environmental degradation. This platform positions a new world headquarters for an international array of scientists, scholars and innovators and lays the foundation to anticipate and respond to existing and emerging challenges and use innovation to purposefully shape and inform our future. For more information visit globalfutures.asu.edu.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211120005125/en/

Contacts

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com

Permalink : https://www.aetoswire.com/news/womenrsquos-entrepreneurship-accelerator-partners-with-the-we-empower-un-sdg-challenge-to-maximize-the-development-impact-of-women-entrepreneurs/en

How Cosmetic Gynaecology is Re-Shaping Women’s Intimate Life

 

Dubai, United Arab Emirates-Thursday 25 November 2021 [ AETOS Wire ]

For women of all ages, access to proper and timely intimate health care services is vital to maintaining a sound quality of life. Physical and emotional changes occur throughout a woman’s natural life cycle, starting from the onset of puberty until after menopause, that require precise, tailor-made treatment at each step of the way.

Females globally seek cosmetic procedures and aesthetic enhancements to aid through key transition phases, to help enhance intimate life and boost self-confidence.

A 2019 study conducted on 196 Saudi Arabian women aged 23 - 55 years on patient satisfaction post-labiaplasty showed an 89% overall satisfaction rate post-op. 90% of the women reported increased self-confidence and self-esteem after aesthetic intervention. The main influencing factors for women to pursue the surgery were aesthetic dissatisfaction with their labia, discomfort when wearing clothing, and painful sexual intercourse.

Similarly, a study on breast augmentation patients conducted in Norway during the same period echoed similar results, showing that motivation to opt for surgery was driven mainly by cosmetic dissatisfaction coupled with physical and practical life impairments. Emotional reasons, including low self-esteem and wanting to increase sexual attractiveness, were also reported.

With the advent of technological advancements and innovation in the medical and healthcare industry, intimate health procedures range from simple in-office procedure with little to no downtime to full transformative surgeries. Patients have the option to choose from a selection of invasive and non-invasive procedures.

Dr. Aseel Abdulrazzak, renowned Specialist OB/GYN and Aesthetic Gynaecologist at CosmeSurge Hospital in Dubai says, “We’re seeing a rise in patients requesting aesthetic gynaecological services; ranging from simple laser procedures for hair removal for increased everyday comfort to surgical procedures such as labiaplasties and breast augmentation for those wishing to enhance themselves physically. It used to be that patients were hesitant of discussing issues related to their sexual health with their physicians, but that stigma is slowly going away. Intimate procedures used to be performed purely to correct a defect, but it is now commonplace and completely valid to want to undergo an intimate procedure just for aesthetic purposes to enhance intimate life.”

Dr. Aseel emphasises the positive role that aesthetic intervention plays in enhancing a woman’s intimate life and how it contributes to overall wellness. Issues faced by older women, especially close to menopause, include, intimate area dryness, skin irritation, loss of volume and asymmetric shape, while younger women tend to suffer more from aesthetic discontent.

Cosmetic gynaecology covers a range of surgical and non-surgical options to transform the appearance of women’s intimate areas for a younger appearance, and to reconstruct pre-existing or new defects from childbirth or other traumas. Lasers and radio-frequency machines are utilised in intimate area rejuvenation and tightening procedures to successfully treat dryness, loose skin, hair removal, pain, itchiness, and offensive odours that hinder a satisfactory intimate life.

“At CosmeSurge, we recognise the importance of feeling like the best version of one’s self, and that starts with recognising that every problem has a solution. We want our patients to feel comfortable in their own skin and not let intimate difficulties get in the way of the rest of their life. Cosmetic medical technology has advanced significantly in the last few years, and procedures today are safe and effective to undergo with almost no complications, when performed by highly trained specialists.” Dr. Aseel adds.

Female intimate health encompasses a large range of both cosmetic and functional treatments and services, and is an important part of maintaining overall good health and boosting confidence. Cosmetic gynaecology is one of the fastest growing specialities globally today, and with the rise in awareness surrounding otherwise taboo subjects and continuous advances in both invasive and non-invasive procedures, is leading to improvements in quality of life of women across all walks of life.

Contacts

SAHARA Communications

Ghyna Kurdy, Senior Account Manager, +971501454324, +97143298996
g.kurdy@saharapr.com / www.saharagcc.com

Permalink : https://www.aetoswire.com/news/how-cosmetic-gynaecology-is-re-shaping-womenrsquos-intimate-life/en

Major Advances in Diagnosing Cancers Associated With the Human Papillomavirus

 VANDŒUVRE-LÈS-NANCY, France-Thursday 25 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- The Institut de Cancérologie de Lorraine [the Lorraine Institute of Oncology, or ICL] in collaboration with the Institut du Cancer Joliot Curie [the Joliot Curie Cancer Institute] in Dakar and the Cerba HealthCare Group has recently finalized research demonstrating that it is possible to diagnose certain cancers caused by the human papillomavirus (HPV) through a simple blood test.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211124006043/en/

Based on the innovative CaptHPV technique, this research recently published in the journal Clinical Cancer Research* raises the prospect of a non-invasive approach to diagnosing certain cancers and optimizing biological monitoring of patients receiving therapy.

A ten-year scientific endeavour combining the expertise of public and private players

Studies conducted in the last twenty years have shown that small fragments of DNA from tumour cells are present in the blood of people with cancer. However, these fragments are difficult to locate since they are mixed in with large amounts of “normal” DNA.

Faced with the difficulty of distinguishing between tumour DNA and non-tumour DNA, ICL teams concentrated their efforts on types of cancers caused by viruses, specifically human papillomaviruses (HPV). They decided to test the hypothesis that it was possible to diagnose cancers associated with these viruses, regardless of the type of cancer or type of virus, in a different way. The ICL teams drew upon an innovative technique called CaptHPV, initially created to analyse tumours. For this new study, the technique was adapted to be used in analysing blood samples. This method makes it possible to detect all types of HPV identified to date and to obtain their full characteristics using what is called next- generation sequencing or NGS.

In 2016, the CaptHPV clinical trial was set up by the ICL in collaboration with a medical team from Senegal (a country with a different prevalence of certain types of HPV than France) and Cerba HealthCare, an expert in tumour biomarker analysis.

Promising results for diagnosing and monitoring patients

At the end of the study, the results obtained in each laboratory were compared. That comparison showed strong consistency between the two types of samples. More specifically, for 77 out of 80 patients with an HPV-associated cancer, the blood sample analysis yielded the same results as the tumour analysis, which is a sensitivity of 95%.

In just one of 54 cases of HPV-negative cancer, the blood test found fragments of viral DNA (a specificity of 98.1%). Furthermore, based on the blood sample, the original method provided a detailed description of the nature and characteristics of the viral genome associated with the tumour.

In certain situations, diagnosing HPV-associated cancer can be difficult using traditional approaches that rely on collecting a tumour tissue sample. This is particularly true for cases of suspected recurrence in a patient originally treated for a given type of tumour who now presents with minimal symptoms and deep lesions that are difficult to distinguish on X-Rays or difficult to access. In these cases, but for all patients broadly speaking, blood sample analysis is a simple, non-invasive alternative to imaging-guided biopsies which can never be entirely risk free.

“Detecting viral DNA circulating in the blood would be an important biological component for optimising biological monitoring of patients during treatment as well as post-therapeutic observation. The fact that the viral profile of the tumour has previously been precisely defined will make it possible to know the main parameters on which the follow-up lab work will be based,” explains Prof. Alexandre Harlé – a university lecturer and hospital practitioner at the ICL/University of Lorraine and the clinical pathologist responsible for the study coordination.

“In the longer term, it is very likely that new treatments -such as immunotherapy or therapeutic vaccine therapy- based on stimulating the immune system and aimed at viral sequences will require accurate prior knowledge of the characteristics of the viral sequences being targeted by these personalised treatments. Here again, being able to define the viral profile, regardless of the type of virus, based on a blood sample that can easily be repeated over time is a very interesting outlook,” states Dr Xavier Sastre-Garau, a pathologist and principal investigator of the study.

Jérôme Sallette, Chief Scientific Officer of Cerba HealthCare, adds: “Liquid biopsies, and non-invasive diagnostic methods more generally, are a major area of research for cancer diagnosis thanks to the power of the next-generation sequencing that the Cerba HealthCare Group has successfully and routinely conducted since 2013. The opportunity offered by our skills in this area and the presence of our Group in Africa have been major advantages for our contribution to the work being done by the ICL. This work once again demonstrates the immense added value of public-private collaborations to advance research and to be able to offer patients and clinicians less invasive tools for earlier diagnoses. They lead to interesting possibilities for combat certain cancers in addition to screening, the importance of which cannot be stressed enough.”

On a more fundamental level, this new approach will undoubtedly improve our knowledge of the biological mechanisms that influence tumour development.

In the long term, the work being conducted specifically on tumours associated with human papillomavirus should pave the way to optimizing diagnosis and monitoring of tumours associated with other viruses. Finally, the sensitivity and specificity observed in this study lay the groundwork for designing similar approaches for other types of tumours characterised by specific genetic alterations.

*Open access article (in English):

https://clincancerres.aacrjournals.org/content/early/2021/06/08/1078-0432.CCR-21-0293.long

Additional information available here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211124006043/en/

Contacts

ICL Press

Alexandra Cravotta

03 83 59 86 05 / 06 86 40 81 50

a.cravotta@nancy.unicancer.fr

Cerba HealthCare Press

Aurélie Le Franc

07 50 12 18 34

aurelie.lefranc@cerbahealthcare.com

Permalink : https://www.aetoswire.com/news/major-advances-in-diagnosing-cancers-associated-with-the-human-papillomavirus/en

Mavenir Announces Commercial Availability of 4G Open RAN-based Outdoor Small Cell

 Currently deployed with Tier 1 European CSP

RICHARDSON, Texas-Thursday 25 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today the commercial availability of its 4G Open RAN small cell for outdoor deployments, expanding the MAVair radio and access portfolio of small cells to meet Communications Service Providers’ (CSPs) growing need for enhanced network capacity and coverage. The solution had already been tested and deployed in commercial operation with a Tier 1 European CSP.

Mavenir’s outdoor small cell (O410) is a customer driven product, that addresses a need for outdoor small cells supporting both distributed and centralized Open RAN architectures. The solution is built on Mavenir’s modular hardware architecture and highly scalable, cloud-native software platforms, the underlying principles which enabled an expedited time-to-market with full architectural and deployment flexibility. Mavenir’s expanded small cells solutions, present a future proof way of building networks that ensures interoperability, vendor competition, element security and reduced operating costs across the RAN. Mavenir’s MAVair Open RAN small cells are market-proven, carrier grade solutions, that are easy to deploy, fully automated, software upgradable, highly scalable and adaptable.

The outdoor small cell supports both Split 2 and S1 interfaces and can be configured remotely for full deployment flexibility and upgradability, especially effective in areas where coverage and capacity from the CSPs macro is not available, is not economically viable, or faces zoning issues, etc. Ideal deployments include rural and remote locations, sites which are constrained by size, power, backhaul, and planning restrictions. The solution is plug and play, with zero-touch provisioning and installation, powered with Power over Ethernet (PoE) and offers interfaces with the same Open RAN CU as the macro network, and with common management with macro.

“By leveraging our modular hardware architecture and cloud-native scalable software, Mavenir is capable of delivering new products in an agile fashion which integrate and work seamlessly with other network components deployed by CSPs. This 4G outdoor small cell is the precursor for a completely new line of 4G and 5G Open RAN-based small cell products with integrated DU, as well as Multi RAT radio access solutions in general,” said Mavenir’s Aniruddho Basu, SVP and GM of Emerging Business.

With the release of the 4G outdoor small cell, Mavenir now has a complete offering of Multi-G (2G/3G/4G/5G), software upgradable, Open RAN-based small cells enabling CSPs to enhance their network capacity and coverage beyond in-building use cases.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211124006039/en/

---

Contacts

Maryvonne Tubb
Mavenir
PR@mavenir.com

Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com

Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com

 

Permalink : https://www.aetoswire.com/news/mavenir-announces-commercial-availability-of-4g-open-ran-based-outdoor-small-cell/en

 

 

Poly Reveals Top Predictions for Workplace Collaboration in 2022

Dubai, UNITED ARAB EMIRATES-Wednesday 24 November 2021 [ AETOS Wire ]

Poly (NYSE: POLY), today announced the top predictions that will shape workplace collaboration, and ultimately, define the future of work in 2022, and beyond.

The highly anticipated return to “normalcy” doesn’t mean going back to our old habits. Hybrid working is here to stay, and the new year brings irreversible changes in the way we perceive -and do- work.

The disruption caused by the global pandemic has forced businesses to enable remote work and tested employees’ ability to embrace new forms of engagement and interaction. The power to drive sustainable, collaborative change will be shared by employers and employees, on an increasingly equal footing. Businesses looking to navigate the year ahead will need to understand, and embrace this fundamental shift to successfully balance technology and transformation.

Prediction 1 - RIP 9-5. Long live “anytime” working

Like a genie that has been released from the bottle, the workers who relished the perks of hybrid and flexible working have no desire to return to corporate life full time. 80% of Europe and the Middle East employees prefer to spend some days working from home, according to Poly’s recent research. They want flexibility, and with the economy picking up and the “great resignation” underway, they have more power to choose how and where they should work from.

“People want work-life balance with flexibility to visit their dentist, attend a school play, or swap their working days around to be able to meet up with an old friend who’s in town. Rather than being an asset that requires managing, employees have adopted a customer persona; they know what they want, why, when and how and they’ll tell you. Ignore them and they’ll go elsewhere,” said Paul Clark, senior vice president for Europe, the Middle East and Africa, Poly.

Prediction 2 – Polymorphic offices supercharged by tools, not toys

Offices will no longer necessarily be physical spaces with defined, individual spots. Future workplaces will be ecosystems of spaces and rooms that match the working habits or needs of different personas. People will no longer go into the office because they must, but because they want specific, person to person interaction. This will lead to significant changes in architecture, real estate, room design and investment in collaboration devices and technologies in future office buildings, as all these disciplines collide to provide the very best work experiences.  

“Organisations that fail to support a flexible workplace in 2022 will struggle to build a collaborative culture. During the pandemic, shrinking networks affected innovation and creativity. Informal chats or unscheduled meetups no longer happen, yet collaborative moments like these contribute to knowledge sharing and problem-solving. Collaboration is required for a happy workforce, with the link between employee well-being and business performance well documented,” adds Clark.

Prediction 3 – Equality: the new imperative

During the pandemic, it was all about business continuity, but companies will need to adopt a people-first philosophy, based on choice. Choice is a great leveler and a catalyst for easy, meaningful and productive collaboration, enabling all workers to engage and perform at their very best. That approach presents a great opportunity for HR, IT, facilities management and the wider business to be more attuned to what employees want from their experience of work. Recent Stanford University research shows that over 40% of workers would actively look elsewhere, if their employers fail to offer hybrid working. 

“The main challenge of flexible, hybrid working is creating equity for all. Clarity and quality of image and sound are essential to better collaboration between colleagues. No matter where people choose (or have) to work from -their car, a meeting room, or home- they will expect to be supported by devices and technologies that guarantee equal inclusivity. Access to reliable communications is key to ensuring people receive the same information, at the same time and to avoid any inadvertent bias,” comments Clark.

About Poly  

Poly (NYSE: POLY) creates premium audio and video products so you can have your best meeting -- anywhere, anytime, every time. Our headsets, video and audio-conferencing products, desk phones, analytics software and services are beautifully designed and engineered to connect people with incredible clarity. They're pro-grade, easy to use and work seamlessly with all the best video and audio-conferencing services. Poly MeetingAI delivers a broadcast quality video conferencing experience with Poly DirectorAI technology which uses artificial intelligence and machine learning to deliver real-time automatic transitions, framing and tracking, while NoiseBlockAI and Acoustic Fence technologies block-out unwanted background noise. With Poly (Plantronics, Inc. – formerly Plantronics and Polycom), you'll do more than just show up, you'll stand out. For more information visit www.Poly.com. 

All other trademarks are the property of their respective owners. 

Contacts

Melwyn Abraham

melwyn@matrixdubai.com

 

Permalink : https://www.aetoswire.com/news/poly-reveals-top-predictions-for-workplace-collaboration-in-2022/en

Andersen Global Fortifies African Foothold with Additional Presence in Gabon

 

SAN FRANCISCO-Friday 19 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Andersen Global enters a Collaboration Agreement with Gabon-based tax firm Caudexco, further bolstering its foothold in the country and expanding its resources in the region.

The full-service firm, established in 2017, provides tax, bookkeeping, payroll and social declaration services, and advises clients on corporate and wealth management matters. With an office in Libreville, the firm serves companies in industries such as oil and gas, manufacturing, commercial and agriculture.

“Our firm’s focus is to seamlessly provide our clients with best-in-class service,” Managing Director Gaston Anguile Ntoke said. “Andersen Global’s international presence through its member and collaborating firms, along with the knowledge and experience of its professionals, enable us to deliver integrated, independent solutions to meet our clients’ local and cross-border needs.”

Andersen Global Chairman and Andersen CEO Mark Vorsatz added, “Caudexco is the most strategic fit for our overall expansion strategy in Africa. Their like-mindedness, experience and expertise enhance our robust team in the region as we continue to add coverage and capabilities for our clients in Africa and globally.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 9,000 professionals worldwide and a presence in over 325 locations through its member firms and collaborating firms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005438/en/

Contacts

Megan Tsuei
Andersen Global
415-764-2700


Permalink : https://www.aetoswire.com/news/andersen-global-fortifies-african-foothold-with-additional-presence-in-gabon/en

Tech Mahindra Partners with TANESCO to Drive Digital Transformation and Improve Efficiency

 One of the biggest Utility Transformation Deals to support future ready applications including Geo Information System, IT Infra/Network, while improving agility and returns on investment through technology-led transformation

DAR ES SALAAM, Tanzania-Tuesday 23 November 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Tech Mahindra, a leading provider of digital transformation, consulting and business re-engineering services & solutions, has partnered with Tanzania Electric Supply Company Ltd. (TANESCO) for one of the biggest Utility Transformation deals. The deal is aimed at enabling digital transformation for TANESCO in order to support future ready applications including Geo Information System, IT Infra/Network, while improving agility and returns on investment through technology-led transformation.

TANESCO, an integrated power utility company, is engaged in the entire value chain of generation, transmission & distribution across Tanzania and is currently transforming itself into a digital enterprise, deploying the full spectrum of technology. As part of the ‘Design Supply, Installation, Implementation, Training and Commissioning of Corporate Management System (CMS) and Supporting Infrastructure,” Tech Mahindra will implement digital solutions such as SAP S4 Hana, SAP Billing, Esri GIS, Huawei Infrastructure, and new edge solutions as Drones, to increase operational efficiency, improve service quality, and enhance customer experience for the power utility company. As part of the collaboration, Tech Mahindra will focus on delivering greater flexibility across Digital IT operations, which includes modernizing core operations and internal applications to drive innovation and accelerate TANESCO’s digital transformation journey.

Ram Ramachandran, SVP and Head, Middle East & Africa, Tech Mahindra, said, “Our partnership with TANESCO is a huge step in our continued journey towards bringing NexGen Utility solutions and service offerings across Africa and Middle East. We are committed to support TANESCO in their digital transformation journey. The deal is aimed at significantly enhancing TANESCO’s digital readiness, and thereby reducing their cost of ownership by automating aspects of their application and infrastructure solutions. We look forward to a strategic relationship with TANESCO to drive innovation in the technology ecosystem while delivering value and quality to end customers.”

Maharage Chande, MD, TANESCO, said, “Our agreement with Tech Mahindra is another step forward in delivering greater flexibility across Digital IT operations. This includes modernizing our core operations, our internal applications to accelerate innovation as we march forward to our vision of becoming a leading regional provider of quality, affordable electricity power. Our collaboration with Tech Mahindra will ultimately help accelerate us providing best services to our Citizens.”

Tech Mahindra is an experienced solution provider in the Energy and Utility business across Power, Water & Wastewater, Renewable, Electric Vehicle, Microgrid, Natural Resources and Mining sectors. The company is currently working with Utility companies in Ethiopia, Ghana, Botswana, Zambia, Angola, South Africa, among others, to help them grow in the right direction by providing digital technology, business consultancy, infrastructure & enterprise security, platform & network services, etc. and boost their quality of service and productivity.

As part of the NXT.NOW™ framework, Tech Mahindra aims to enhance human centric experiences for businesses. This means focusing on investing in emerging technologies and solutions that enable digital transformation to better meet the evolving needs of its customers through our DigitALL framework.

Connect with us on www.techmahindra.com

Our Social Media Channels

Facebook: https://www.facebook.com/TechMahindra

Twitter: https://twitter.com/Tech_Mahindra

LinkedIn: https://www.linkedin.com/company/tech-mahindra/

YouTube: https://www.youtube.com/user/techmahindra09

View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005648/en/

Contacts

For more information on Tech Mahindra, please contact:

Abhilasha Gupta, Global Corporate Communications and Public Affairs

Email: Abhilasha.Gupta@TechMahindra.com; media.relations@techmahindra.com

Permalink : https://www.aetoswire.com/news/tech-mahindra-partners-with-tanesco-to-drive-digital-transformation-and-improve-efficiency/en

Hikma and Winterlight Labs PoC Collaboration

 Hikma and Winterlight Labs collaborate to develop biomarkers for Schizophrenia patients in MENA

Amman, Jordan-Tuesday 23 November 2021 [ AETOS Wire ]

Hikma Pharmaceuticals PLC (‘Hikma’), the multinational pharmaceutical company, announces a collaboration agreement with Winterlight Labs, Inc., a Hikma Ventures portfolio company, to conduct a Proof-of-Concept (PoC) study to validate Winterlight Labs’ speech-based biomarkers for schizophrenia patients in the Arabic language.

The first of its kind study in the region is sponsored by Hikma and will be conducted in coordination with leading psychiatric care organizations across 4 countries in the MENA – Algeria, Egypt, Jordan and Saudi Arabia. The study has already started in Jordan, with the remaining sites expected to start in the coming weeks.

This regional study is an important step towards proving the validity of vocal biomarkers for monitoring the progression and severity of schizophrenia in patients. Winterlight Labs’ proprietary AI, through a series of digitally administered and recorded tasks, can extract over 500 acoustic and linguistic features from short audio snippets to assess a patient’s mental health accurately and objectively.

Commenting on the agreement, David Olafsson, Head of Global Clinical Research at Hikma, said, “We are excited to lead this research using Winterlight Labs’ vocal biomarkers across the MENA markets where we are conducting the study, and are positive that this pioneering digital tool will transform the way that schizophrenia is monitored – thereby offering better care for patients while simultaneously easing the burden on their caregivers and healthcare providers.”

Hikma Ventures, Hikma Pharmaceuticals’ strategic venture capital arm, led Winterlight Labs’ Series A investment in November 2019 and has made 12 investments to date in global digital health companies. Commenting on this milestone collaboration, Faisal Al-Husry, Associate at Hikma Ventures, said, “With the rise of digital health platforms globally and the increased focus on remote patient monitoring, we believe that it is only a matter of time before digital monitoring tools – like Winterlight Labs’ vocal biomarkers – become the norm in clinical practice. We are happy to support Winterlight Labs’ development and are eager for Hikma to introduce these tools to patients and healthcare customers in the MENA region.”

In her remarks on the partnership, Jessica Robin, Director of Clinical Research at Winterlight Labs, said, “This collaboration is very exciting as it enables us to make our platform available for Arabic-speaking patients. The PoC will help validate our schizophrenia assessment program and enable us to reach a wider patient cohort. We look forward to working with Hikma and leveraging their reach in MENA in combination with our technology.”

About Hikma Ventures
Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.

For more information, please visit www.hikmaventures.com.

---

Contacts

Hikma Pharmaceuticals PLC

Dana Alhusseini, Communications Manager  +962 (6) 5802900 Dalhusseini@hikma.com

 

Permalink : https://www.aetoswire.com/news/hikma-and-winterlight-labs-poc-collaboration/en